Appeals system and its outcomes in National Health Insurance in Taiwan

Swu Jane Lin, Shih Chen Kuo, Yea-Huei Kao

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: Prior authorization has been used extensively as one of the mechanisms to control costs and ensure quality of care by the National Health Insurance (NHI) plan in Taiwan. An appeals system, the Dispute Mediation Committee (DMC), independent of the NHI, is available for interested parties to dispute denials of prior authorization. Currently, medications for Alzheimer's disease constitute the largest category of appeals. OBJECTIVE: To describe the appeals system and analyze outcomes of cases of medications for Alzheimer's disease submitted to the Bureau of NHI (BNHI) for prior authorization and to the DMC for appeals. METHODS: Prescriptions of donepezil and rivastigmine submitted for prior authorization from 2000 through 2002 were analyzed. Cases denied prior authorization and later submitted as appeals to the DMC were summarized with descriptive and bivariate methods. RESULTS: A total of 12 237 cases of donepezil and 6975 cases of rivastigmine were submitted to the BNHI for prior authorization; among them, 72.6% of donepezil and 66.5% of rivastigmine cases received authorization. Among the thousands of cases denied prior authorization, 124 appealed to the DMC for dispute resolution. The result of the majority of the appeals (111 [89.5%]) was to uphold the BNHI denial decision. Most of the appeals were denied because of the lack of appropriate exclusion of other possible causes of dementia. CONCLUSIONS: Most appeals were again denied after expert review. Better education concerning utilization guidelines and a platform for insurer, insuree, and physician to dialog are needed to improve the effectiveness and efficiency of the appeals system.

Original languageEnglish
Pages (from-to)506-511
Number of pages6
JournalAnnals of Pharmacotherapy
Volume40
Issue number3
DOIs
Publication statusPublished - 2006 Mar 1

Fingerprint

Dissent and Disputes
Rivastigmine
National Health Programs
Taiwan
Alzheimer Disease
Insurance Carriers
Cost Control
Quality of Health Care
Systems Analysis
Prescriptions
Dementia
Guidelines
Physicians
Education
donepezil

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Lin, Swu Jane ; Kuo, Shih Chen ; Kao, Yea-Huei. / Appeals system and its outcomes in National Health Insurance in Taiwan. In: Annals of Pharmacotherapy. 2006 ; Vol. 40, No. 3. pp. 506-511.
@article{91b57730fb9140b9ae61c69d00649168,
title = "Appeals system and its outcomes in National Health Insurance in Taiwan",
abstract = "BACKGROUND: Prior authorization has been used extensively as one of the mechanisms to control costs and ensure quality of care by the National Health Insurance (NHI) plan in Taiwan. An appeals system, the Dispute Mediation Committee (DMC), independent of the NHI, is available for interested parties to dispute denials of prior authorization. Currently, medications for Alzheimer's disease constitute the largest category of appeals. OBJECTIVE: To describe the appeals system and analyze outcomes of cases of medications for Alzheimer's disease submitted to the Bureau of NHI (BNHI) for prior authorization and to the DMC for appeals. METHODS: Prescriptions of donepezil and rivastigmine submitted for prior authorization from 2000 through 2002 were analyzed. Cases denied prior authorization and later submitted as appeals to the DMC were summarized with descriptive and bivariate methods. RESULTS: A total of 12 237 cases of donepezil and 6975 cases of rivastigmine were submitted to the BNHI for prior authorization; among them, 72.6{\%} of donepezil and 66.5{\%} of rivastigmine cases received authorization. Among the thousands of cases denied prior authorization, 124 appealed to the DMC for dispute resolution. The result of the majority of the appeals (111 [89.5{\%}]) was to uphold the BNHI denial decision. Most of the appeals were denied because of the lack of appropriate exclusion of other possible causes of dementia. CONCLUSIONS: Most appeals were again denied after expert review. Better education concerning utilization guidelines and a platform for insurer, insuree, and physician to dialog are needed to improve the effectiveness and efficiency of the appeals system.",
author = "Lin, {Swu Jane} and Kuo, {Shih Chen} and Yea-Huei Kao",
year = "2006",
month = "3",
day = "1",
doi = "10.1345/aph.1G437",
language = "English",
volume = "40",
pages = "506--511",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "3",

}

Appeals system and its outcomes in National Health Insurance in Taiwan. / Lin, Swu Jane; Kuo, Shih Chen; Kao, Yea-Huei.

In: Annals of Pharmacotherapy, Vol. 40, No. 3, 01.03.2006, p. 506-511.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Appeals system and its outcomes in National Health Insurance in Taiwan

AU - Lin, Swu Jane

AU - Kuo, Shih Chen

AU - Kao, Yea-Huei

PY - 2006/3/1

Y1 - 2006/3/1

N2 - BACKGROUND: Prior authorization has been used extensively as one of the mechanisms to control costs and ensure quality of care by the National Health Insurance (NHI) plan in Taiwan. An appeals system, the Dispute Mediation Committee (DMC), independent of the NHI, is available for interested parties to dispute denials of prior authorization. Currently, medications for Alzheimer's disease constitute the largest category of appeals. OBJECTIVE: To describe the appeals system and analyze outcomes of cases of medications for Alzheimer's disease submitted to the Bureau of NHI (BNHI) for prior authorization and to the DMC for appeals. METHODS: Prescriptions of donepezil and rivastigmine submitted for prior authorization from 2000 through 2002 were analyzed. Cases denied prior authorization and later submitted as appeals to the DMC were summarized with descriptive and bivariate methods. RESULTS: A total of 12 237 cases of donepezil and 6975 cases of rivastigmine were submitted to the BNHI for prior authorization; among them, 72.6% of donepezil and 66.5% of rivastigmine cases received authorization. Among the thousands of cases denied prior authorization, 124 appealed to the DMC for dispute resolution. The result of the majority of the appeals (111 [89.5%]) was to uphold the BNHI denial decision. Most of the appeals were denied because of the lack of appropriate exclusion of other possible causes of dementia. CONCLUSIONS: Most appeals were again denied after expert review. Better education concerning utilization guidelines and a platform for insurer, insuree, and physician to dialog are needed to improve the effectiveness and efficiency of the appeals system.

AB - BACKGROUND: Prior authorization has been used extensively as one of the mechanisms to control costs and ensure quality of care by the National Health Insurance (NHI) plan in Taiwan. An appeals system, the Dispute Mediation Committee (DMC), independent of the NHI, is available for interested parties to dispute denials of prior authorization. Currently, medications for Alzheimer's disease constitute the largest category of appeals. OBJECTIVE: To describe the appeals system and analyze outcomes of cases of medications for Alzheimer's disease submitted to the Bureau of NHI (BNHI) for prior authorization and to the DMC for appeals. METHODS: Prescriptions of donepezil and rivastigmine submitted for prior authorization from 2000 through 2002 were analyzed. Cases denied prior authorization and later submitted as appeals to the DMC were summarized with descriptive and bivariate methods. RESULTS: A total of 12 237 cases of donepezil and 6975 cases of rivastigmine were submitted to the BNHI for prior authorization; among them, 72.6% of donepezil and 66.5% of rivastigmine cases received authorization. Among the thousands of cases denied prior authorization, 124 appealed to the DMC for dispute resolution. The result of the majority of the appeals (111 [89.5%]) was to uphold the BNHI denial decision. Most of the appeals were denied because of the lack of appropriate exclusion of other possible causes of dementia. CONCLUSIONS: Most appeals were again denied after expert review. Better education concerning utilization guidelines and a platform for insurer, insuree, and physician to dialog are needed to improve the effectiveness and efficiency of the appeals system.

UR - http://www.scopus.com/inward/record.url?scp=33645092641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645092641&partnerID=8YFLogxK

U2 - 10.1345/aph.1G437

DO - 10.1345/aph.1G437

M3 - Article

VL - 40

SP - 506

EP - 511

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 3

ER -